IL280083A - Pharmaceutical dosage form which can be administered orally and has modified release - Google Patents

Pharmaceutical dosage form which can be administered orally and has modified release

Info

Publication number
IL280083A
IL280083A IL280083A IL28008321A IL280083A IL 280083 A IL280083 A IL 280083A IL 280083 A IL280083 A IL 280083A IL 28008321 A IL28008321 A IL 28008321A IL 280083 A IL280083 A IL 280083A
Authority
IL
Israel
Prior art keywords
dosage form
administered orally
pharmaceutical dosage
modified release
release
Prior art date
Application number
IL280083A
Other languages
Hebrew (he)
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/043,567 external-priority patent/US10905667B2/en
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of IL280083A publication Critical patent/IL280083A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
IL280083A 2018-07-24 2021-01-11 Pharmaceutical dosage form which can be administered orally and has modified release IL280083A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18185127 2018-07-24
US16/043,567 US10905667B2 (en) 2018-07-24 2018-07-24 Orally administrable modified-release pharmaceutical dosage form
PCT/EP2019/069561 WO2020020789A1 (en) 2018-07-24 2019-07-19 Pharmaceutical dosage form which can be administered orally and has modified release

Publications (1)

Publication Number Publication Date
IL280083A true IL280083A (en) 2021-03-01

Family

ID=67314781

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280083A IL280083A (en) 2018-07-24 2021-01-11 Pharmaceutical dosage form which can be administered orally and has modified release

Country Status (22)

Country Link
EP (1) EP3826627B1 (en)
JP (1) JP2021532113A (en)
KR (1) KR20210035235A (en)
CN (1) CN112469402A (en)
AU (1) AU2019311234A1 (en)
BR (1) BR112020026644A2 (en)
CA (1) CA3107169A1 (en)
CL (1) CL2021000160A1 (en)
CO (1) CO2021000450A2 (en)
CR (1) CR20210043A (en)
DO (1) DOP2021000015A (en)
EC (1) ECSP21003707A (en)
IL (1) IL280083A (en)
JO (1) JOP20210019A1 (en)
MA (1) MA53368A (en)
MX (1) MX2021000904A (en)
PE (1) PE20210415A1 (en)
PH (1) PH12021550170A1 (en)
SG (1) SG11202100369WA (en)
TW (1) TW202019402A (en)
UY (1) UY38308A (en)
WO (1) WO2020020789A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202112359A (en) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 THE USE OF sGC ACTIVATORS FOR THE TREATMENTOF OPHTHALMOLOGIC DISEASES
CN112557533A (en) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 Analysis method of engletzin
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ATE72111T1 (en) 1987-01-14 1992-02-15 Ciba Geigy Ag THERAPEUTIC SYSTEM FOR POORLY SOLUBLE ACTIVE INGREDIENTS.
DE19747261A1 (en) 1997-10-25 1999-04-29 Bayer Ag Single-chamber osmotic pharmaceutical release system
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19834044A1 (en) 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
ATE433318T1 (en) * 1999-02-10 2009-06-15 Pfizer Prod Inc OSMOTIC SYSTEM FOR ADMINISTRATION OF ACTIVE INGREDIENTS CONTAINING SOLID AMORPHOUS DISPERSIONS
AR031176A1 (en) 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms
DE102008059206A1 (en) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
DE102010021637A1 (en) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
EA201390060A1 (en) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх ANNELED PYRIMIDINES AND TRIAZINES AND THEIR APPLICATION FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
DE102010040233A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
DE102010043379A1 (en) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use
DE102011007272A1 (en) * 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
UY34856A (en) * 2012-07-03 2013-12-31 Bayer Pharma AG PHARMACEUTICAL PRESENTATION FORMS CONTAINING 5-CHLORO-N - ({(5S) -2-OXO-3- [4- (3-OXO-4- MORPHOLINYL) -PHENYL] -1,3-OXAZOLIDIN-5-IL} -METIL) -2-THIOFENCARBOXAMIDE
MX2020005646A (en) 2017-12-01 2020-08-20 Bayer Pharma AG METHOD FOR PRODUCING (3<i>S</i>)-3-(4-CHLOR-3-{[(2<i>S,</i>3<i>R< /i>)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AMINO}PHE NYL)-3-CYCLO-PROPYLPROPANOIC ACID AND THE CRYSTALLINE FORM THEREOF FOR USE AS A PHARMACEUTICAL INGREDIENT.

Also Published As

Publication number Publication date
UY38308A (en) 2020-02-28
CA3107169A1 (en) 2020-01-30
TW202019402A (en) 2020-06-01
CN112469402A (en) 2021-03-09
MX2021000904A (en) 2021-03-31
EP3826627A1 (en) 2021-06-02
ECSP21003707A (en) 2021-02-26
JOP20210019A1 (en) 2021-01-24
CR20210043A (en) 2021-03-09
PH12021550170A1 (en) 2021-09-13
EP3826627B1 (en) 2023-10-18
MA53368A (en) 2021-06-02
CL2021000160A1 (en) 2021-06-04
SG11202100369WA (en) 2021-02-25
JP2021532113A (en) 2021-11-25
KR20210035235A (en) 2021-03-31
CO2021000450A2 (en) 2021-01-29
BR112020026644A2 (en) 2021-03-23
EP3826627C0 (en) 2023-10-18
DOP2021000015A (en) 2021-02-15
AU2019311234A1 (en) 2021-02-04
WO2020020789A1 (en) 2020-01-30
PE20210415A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
IL280083A (en) Pharmaceutical dosage form which can be administered orally and has modified release
PL3487505T3 (en) Administration and dosage of diaminophenothiazines
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
IL304732A (en) Modified release orally administered amino acid formulations
HK1218884A1 (en) Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
IL265970B (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
EP3400964A4 (en) Taste-masked and orally administered pharmaceutical preparation containing varenicline or pharmaceutically acceptable salt thereof
EP3498280A4 (en) Administration and dosage of therapeutic agent for endometriosis
IL276323A (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
ZA201800470B (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
IL267219A (en) Novel tebipenem pivoxil immediate and modified release oral dosage forms
HK1245646A1 (en) Pharmaceutical composition for oral administration
IL273240A (en) Oral-surface administered preparation for the prevention of illnesses acquired via the oral cavity and the pharynx
IL261929B (en) Stable pharmaceutical compositions for topical administration and uses thereof
PL3326619T3 (en) Solid oral pharmaceutical compositions comprising tenofovir and emtricitabine
ZA202110948B (en) Pharmaceutical dosage forms and methods for their production
EP4052699A4 (en) Orally administered solid dosage form drug
SI3236950T1 (en) Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof
SG11202101547WA (en) Pharmaceutical composition for oral administration
EP3552632A4 (en) Medicinal composition for treating and preventing chronic disease
PL3277266T3 (en) Oral solid dosage form of amlodipine and veterinary uses thereof
IL291196A (en) Drug dosage determination devices and methods
EP3661486A4 (en) Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof
GB201710382D0 (en) Administration and dosage of Diaminophenothiazines
GB201612863D0 (en) Administration and dosage of diaminophenothiazines